QST and Neuropathic Pain

Inclusion Criteria

• •Minimum baseline pain rating of 50mm on a 100mm NRS in the painful area
• •Chronic pain of at least 6 months
• •Subject satisfies standard criteria in the study centre for SCS implantation and the NICE 159 criteria for management of intractable neuropathic pain.
• •Subject satisfies standard criteria in the study centre for ONS implantation and the NICE 452 criteria for intractable chronic migraine.
• •Patients who have given their written informed consent.
• •Patient is able and willing to comply with study procedures and follow up schedule.
• •Female patients of childbearing age who is or plans on becoming pregnant during the course of the study
• •Patients who have undergone radiofrequency or injection therapy at or on a target neural structure (DRG) during the past 90 days
• •Patients with diabetes or any underlying neurological condition.
• •Patients known to have a condition that in the investigator's judgment precludes participation in the study.
• •Patients who have received an investigational drug or have used an investigational device in the 30 days preceding to study entry